Sembragiline (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names EVT-302, RG-1577, RO-4602522) is a selective and reversible monoamine oxidase B (MAO-B) inhibitor which is or was under development for the treatment of Alzheimer's disease.[1][2][3][4] It was also under development for the treatment of smoking withdrawal, but development for this indication was discontinued.[1][2][3] The drug is taken by mouth.[1][4] Sembragiline is or was being developed by Roche and Evotec SE.[1][2][3]

References

  1. ^ a b c d e "Sembragiline". AdisInsight. 5 November 2023. Retrieved 24 February 2025.
  2. ^ a b c "Delving into the Latest Updates on Sembragiline with Synapse". Synapse. 22 February 2025. Retrieved 24 February 2025.
  3. ^ a b c "Sembragiline". ALZFORUM. 20 November 2015. Retrieved 24 February 2025.
  4. ^ a b Lin P, Sun J, Cheng Q, Yang Y, Cordato D, Gao J (December 2021). "The Development of Pharmacological Therapies for Alzheimer's Disease". Neurology and Therapy. 10 (2): 609–626. doi:10.1007/s40120-021-00282-z. PMC 8571471. PMID 34532845. Sembragiline (also known as RO4602522, RG1577 and EVT302) is a potent, selective and reversible monoamine oxidase B (MAO-B) inhibitor developed to treat AD. A PET study revealed almost complete inhibition of central MAO-B at an oral dose of 1 mg per day in AD patients; however, no cognitive benefits were detected after treatment [91].
Allikas: https://en.wikipedia.org/wiki/Sembragiline
No tags for this post.